Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is an open label, prospective study to evaluate therapeutic potential of Tazarotene 0.1%
cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled
into the study. Tazarotene will be used for up to 24 weeks and patients will be followed for
up to 12 months.